苯并噻唑-4-醛 | 1213833-90-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 苯并噻唑-4-醛
• 英文名称: 1,3-benzothiazole-4-carbaldehyde
• 英文别名: benzo[d]thiazole-4-carbaldehyde；Benzo[d]thiazole-4-carbaldehyde
• CAS: 1213833-90-9
• 化学式: C₈H₅NOS
• 分子量: 163.2
• InChiKey: VCNWADMZUYTNIH-UHFFFAOYSA-N

物化性质

• 沸点：
  311.4±15.0 °C(Predicted)
• 密度：
  1.384±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  苯并噻唑-4-醛 在 titanium(IV) isopropylate 、 氨 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 (1R,2S,5S)-N-(benzo[d]thiazol-4-yl(cyano)methyl)-3-((S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
  参考文献：
  名称：

  [EN] MPRO TARGETING ANTIVIRAL COMPOUNDS
  [FR] COMPOSÉS ANTIVIRAUX CIBLANT LES MPRO

  摘要：

  公开了根据式（I）的新型病毒 Mpro 抑制剂、它们的药学上可接受的盐及其药物组合物。还公开了使用此类化合物和组合物抑制 Mpro 和/或治疗各种病毒感染的方法；特别是与冠状病毒有关的病毒感染。本公开的化合物和组合物在治疗广谱冠状病毒方面可能特别有用。

  公开号：

  WO2023180189A1
• 作为产物：
  描述：

  4-甲基苯并噻唑(7ci,8ci,9ci) 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 N-甲基吗啉氧化物 作用下， 以 1,2-二氯乙烷 、 乙腈 为溶剂， 反应 2.0h， 生成 苯并噻唑-4-醛
  参考文献：
  名称：

  WO2024129896A1

  摘要：

  公开号：

文献信息

• REVERSE-TURN MIMETICS AND METHOD RELATING THERETO
  申请人：Moon Sung Hwan

  公开号：US20100222303A1

  公开（公告）日：2010-09-02

  Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins as well as their prodrugs are disclosed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds and prodrugs for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

  本发明揭示了限制构象的化合物，其模拟生物活性肽和蛋白质的反转区域的二级结构以及它们的前药。这种反转区域模拟结构和前药在广泛的领域中具有实用性，包括用作诊断和治疗剂。本发明还揭示了包含这种反转区域模拟结构的库以及筛选相同以识别生物活性成员的方法。本发明还涉及使用这种化合物和前药来抑制或治疗由Wnt信号通路调节的疾病，例如癌症，特别是结肠直肠癌，与血管成形术相关的再狭窄，多囊肾病，异常血管生成疾病，类风湿性关节炎疾病，结节性硬化症，阿尔茨海默病，过度生长或脱发，或溃疡性结肠炎。
• Reverse-turn mimetics and method relating thereto
  申请人：Choongwae Pharma Corporation

  公开号：US08138337B2

  公开（公告）日：2012-03-20

  Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins as well as their prodrugs are disclosed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds and prodrugs for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

  本发明揭示了构象受限化合物，其模拟生物活性肽和蛋白质的反转区域的二级结构，以及它们的前药。这样的反转区模拟结构和前药在广泛的领域中具有实用性，包括用作诊断和治疗剂。本发明还揭示了包含这些反转区模拟结构的库，以及筛选这些库以识别生物活性成员的方法。本发明还涉及使用这样的化合物和前药来抑制或治疗由Wnt信号通路调节的疾病，如癌症，特别是结肠直肠癌，与血管成形术相关的再狭窄，多囊肾病，异常血管生成疾病，类风湿性关节炎疾病，结节性硬化症，阿尔茨海默病，过度毛发生长或脱发，或溃疡性结肠炎。
• SULFONAMIDE COMPOUND OR SALT THEREOF
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP3466934A1

  公开（公告）日：2019-04-10

  The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents -NH-; X4 represents a hydrogen atom or the like; R1 represents -C(R11)(R12)- or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.

  本发明提供了一种具有核糖核苷酸还原酶抑制活性的新型磺酰胺化合物或其盐，以及含有该化合物作为活性成分的药物组合物。 由式(I)代表的化合物[其中，X1代表氧原子或类似物；X2代表氧原子；X3代表-NH-；X4代表氢原子或类似物；R1代表-C(R11)(R12)-或类似物；R11和R12相同或不同且各自代表氢原子或类似物；R2代表任选取代的C6-C14芳烃基团或类似物；R3代表任选取代的C6-C14芳烃基团或类似物；R4代表氢原子或类似物]或其盐。
• ANTITUMOR AGENT
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP3718545A1

  公开（公告）日：2020-10-07

  The present invention provides a method of enhancing an antitumor effect by a compound strongly inhibiting ribonucleotide reductase (RNR) or a salt thereof. A combination formulation involving combined administration of a sulfonamide compound represented by Formula (I) [In the formula, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents -NH-; X4 represents a hydrogen atom or the like; R1 represents -C(R11) (R12)- or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof, having RNR inhibitory activity, and other antitumor agent(s).

  本发明提供了一种通过强抑制核糖核苷酸还原酶（RNR）的化合物或其盐增强抗肿瘤效果的方法。 一种组合制剂涉及联合给药由式(I)代表的磺酰胺化合物[式中，X1代表氧原子或类似物；X2代表氧原子；X3代表-NH-；X4代表氢原子或类似物；R1代表-C(R11)(R12)-或类似物；R11和R12相同或不同，各自代表氢原子或类似物；R2代表任选取代的C6-C14芳烃基团或类似物；R3代表任选取代的C6-C14芳烃基团或类似物；R4代表氢原子或类似物]或其盐，具有RNR抑制活性，以及其他抗肿瘤剂。
• Organic semiconductor formulations
  申请人：Flexterra, Inc.

  公开号：US10043978B2

  公开（公告）日：2018-08-07

  The present teachings relate to organic semiconductor formulations including an organic semiconducting compound in a liquid medium, where the liquid medium includes (1) a compound in liquid state that has electronic properties complementary to the electronic structure of the organic semiconducting compound and optionally (2) a solvent or solvent mixture for solubilizing the organic semiconducting compound. The present formulations can be used as inks in the fabrication of organic semiconductor devices.

  本发明涉及有机半导体制剂，包括液体介质中的有机半导体化合物，其中液体介质包括（1）液态化合物，该化合物具有与有机半导体化合物电子结构互补的电子特性，以及（2）用于溶解有机半导体化合物的溶剂或溶剂混合物。本制剂可用作制造有机半导体器件的油墨。